Cocrystal Pharma Inc (COCP):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8034)
◆英語タイトル:Cocrystal Pharma Inc (COCP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8034
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:51
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Cocrystal Pharma Inc (Cocrystal Pharma), formerly Biozone Pharmaceuticals Inc, a subsidiary of MusclePharm Corp, is a clinical stage biotechnology company that discovers and develops novel antiviral therapeutics. The company provides treatments for chronic viral diseases. Its pipeline products include Nucleoside NS5B, NS5A, NNI NS5B, and NS3 Helicase. Cocrystal Pharma offers products such as non nucleoside inhibitors, novel pan-genotypic nucleoside prodrugs, and helicase inhibitors. The company’s novel pan-genotypic nucleoside pro-drugs are used in non-toxic, resisting drug-drug interactions, barrier to drug resistance, short duration treatment and others. Its novel antiviral therapeutics is used in treatments for serious and chronic viral diseases. The company operates in Tucker and Bothell. Cocrystal Pharma is headquartered in Tucker, Georgia, the US.

Cocrystal Pharma Inc (COCP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Cocrystal Pharma Raises USD4 Million in Financing 11
BioZone Pharma Raises USD3.5 Million in Venture Financing 12
BioZone Pharma Raises USD2 Million in Venture Financing 13
BioZone Pharma Raises USD0.8 Million in Venture Financing 14
BioZone Pharma Raises USD0.25 Million in Venture Financing 15
Biozone Pharma Raises USD2.3 Million in Venture Financing 16
Partnerships 17
Cocrystal Pharma Enters into Clinical Trial Agreement with Humanity & Health Research Centre 17
Cocrystal Pharma Enters into Research Agreement with HitGen and InterX 18
Merger 19
RFS Pharma Merges with Cocrystal Pharma 19
BioZone Pharma Completes Merger With Cocrystal Discovery In Reverse Merger Transaction 20
Licensing Agreements 21
Cocrystal Pharma Enters into Licensing Agreement with Duke University and Emory University 21
Cocrystal Pharma Enters into Licensing Agreement with Emory University 23
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030 24
Equity Offering 25
Cocrystal Pharma Prices Public Offering of Shares for USD8 Million 25
Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 26
Cocrystal Pharma Raises USD4 Million in Private Placement of Shares 27
Cocrystal Pharma Raises USD5 Million in Private Placement of Shares 28
Debt Offering 29
Cocrystal Pharma Raises USD0.05 Million in Public Offering of Notes Due 2014 29
Cocrystal Pharma Raises USD1 Million in Private Placement of Notes 30
Cocrystal Pharma Inc – Key Competitors 31
Cocrystal Pharma Inc – Key Employees 32
Cocrystal Pharma Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 09, 2018: Cocrystal Pharma reports 2018 second quarter financial results and provides corporate update 34
May 11, 2018: Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update 36
Mar 22, 2018: Cocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business Outlook 38
Nov 08, 2017: Cocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company Update 40
Aug 08, 2017: Cocrystal Pharma Announces Filing 2017 Second Quarter Financial Statements and Provides Company Update 41
Apr 03, 2017: Cocrystal Pharma Reports Financial Results for Fourth Quarter & Year Ended December 31, 2016 and Provides Company Update 42
Corporate Communications 44
Mar 12, 2018: Cocrystal Pharma Announces Uplist to The Nasdaq Capital Market 44
Jun 01, 2017: James J. Martin Appointed as Chief Financial Officer of Cocrystal Pharma 45
Legal and Regulatory 46
Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 46
Clinical Trials 47
May 10, 2018: Cocrystal Pharma to Present at the Fred Hutch and Merck Infectious Disease Summit 47
Apr 03, 2018: Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus 48
Aug 15, 2017: Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection 49
Feb 16, 2017: Cocrystal Pharma to Present Clinical Data on its Potent Pan-genotypic NS5B Non-nucleoside Inhibitor CC-31244 at the Asian Pacific Association for the Study of the Liver Annual Meeting 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cocrystal Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cocrystal Pharma Raises USD4 Million in Financing 11
BioZone Pharma Raises USD3.5 Million in Venture Financing 12
BioZone Pharma Raises USD2 Million in Venture Financing 13
BioZone Pharma Raises USD0.8 Million in Venture Financing 14
BioZone Pharma Raises USD0.25 Million in Venture Financing 15
Biozone Pharma Raises USD2.3 Million in Venture Financing 16
Cocrystal Pharma Enters into Clinical Trial Agreement with Humanity & Health Research Centre 17
Cocrystal Pharma Enters into Research Agreement with HitGen and InterX 18
RFS Pharma Merges with Cocrystal Pharma 19
BioZone Pharma Completes Merger With Cocrystal Discovery In Reverse Merger Transaction 20
Cocrystal Pharma Enters into Licensing Agreement with Duke University and Emory University 21
Cocrystal Pharma Enters into Licensing Agreement with Emory University 23
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030 24
Cocrystal Pharma Prices Public Offering of Shares for USD8 Million 25
Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 26
Cocrystal Pharma Raises USD4 Million in Private Placement of Shares 27
Cocrystal Pharma Raises USD5 Million in Private Placement of Shares 28
Cocrystal Pharma Raises USD0.05 Million in Public Offering of Notes Due 2014 29
Cocrystal Pharma Raises USD1 Million in Private Placement of Notes 30
Cocrystal Pharma Inc, Key Competitors 31
Cocrystal Pharma Inc, Key Employees 32
Cocrystal Pharma Inc, Other Locations 33
Cocrystal Pharma Inc, Subsidiaries 33

List of Figures
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cocrystal Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Cocrystal Pharma Inc (COCP):製薬・医療:M&Aディール及び事業提携情報(Cocrystal Pharma Inc (COCP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆